Similar articles

• Investigation into the structure-activity relationship of novel concentration dependent, dual action T-type calcium channel agonists/antagonists.

  McCalmont WF, Patterson JR, Lindenmuth MA, Heady TN, Haverstick DM, Gray LS, Macdonald TL. McCalmont WF, et al. Bioorg Med Chem. 2005 Jun 1;13(11):3821-39. doi: 10.1016/j.bmc.2005.03.004. Bioorg Med Chem. 2005. PMID: 15863008
• Factors modifying the tissue selectivity of calcium-antagonists.

  Spedding M, Fraser S, Clarke B, Patmore L. Spedding M, et al. J Neural Transm Suppl. 1990;31:5-16. J Neural Transm Suppl. 1990. PMID: 1963634 Review.
• Calcium antagonists and vasodilatation.

  Godfraind T. Godfraind T. Pharmacol Ther. 1994 Oct;64(1):37-75. doi: 10.1016/0163-7258(94)90033-7. Pharmacol Ther. 1994. PMID: 7846116 Review.
• [Experimental pharmacology of calcium antagonists].

  Godfraind T. Godfraind T. Therapie. 1993 Nov-Dec;48 Spec No:637-49. Therapie. 1993. PMID: 8091349 Review. French.
• Synthesis and calcium channel-modulating effects of alkyl (or cycloalkyl) 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridyl-5-pyridinecarboxylate racemates and enantiomers.

  Ramesh M, Matowe WC, Akula MR, Vo D, Dagnino L, Li-Kwong-Ken MC, Wolowyk MW, Knaus EE. Ramesh M, et al. J Med Chem. 1998 Feb 12;41(4):509-14. doi: 10.1021/jm9704006. J Med Chem. 1998. PMID: 9484501